Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 1475

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 6
Chunk 1475
---
4 (the “Stockholder Approval Date”). The Series A Warrants expire
five years after the Stockholder Approval Date or November 6, 2029, and the Series B Warrants will expire 18 months after the Stockholder
Approval Date, or May 6, 2026. 

As compensation for acting as the placement agent
for the Private Placement, the Company issued to H.C. Wainwright & Co., LLC warrants to purchase up to 43,479 shares of stock (the
“September 2024 Agent Warrants”). The September 2024 Agent Warrants have substantially the same terms as the Series A Warrants,
except that the September 2024 Agent Warrants have an exercise price equal to $8.63 per share.

The following table presents a summary of the
activity for the Company’s equity-classified warrants during the year ended December 31, 2023:

     Number of Warrants   Weighted Average Exercise Price   Weighted Average Remaining Contractual Life (Years)   Total outstanding, December 31, 2022   -   $-    -   Reclassified from derivative liabilities   3,870    327.89    4.15   Granted   51,942    373.00    5.00   Exercised   (3,075)   368.16    5.00   Forfeited   -    -    -   Expired   -    -    -   Total outstanding, December 31, 2023   52,737   $369.98    4.47   Total exercisable, December 31, 2023   52,737   $369.98    4.47  

F-22

During the year ended December 31, 2023, the
Company received aggregate cash proceeds of $1,131,771 upon the exercise of 525 Bridge Warrants, 1,000 Non-tradeable Warrants, and 1,550
Tradeable Warrants.

The following table presents a summary of the
activity for the Company’s equity-classified warrants during the year ended December 31, 2024:

     Number of Warrants   Weighted Average Exercise Price   Weighted Average Remaining Contractual Life